The Parkin'Play study: Protocol of a phase II randomized controlled trial to assess the effects of a health game on cognition in Parkinson's disease by Weijer, S.C.F. van de et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/168194
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
STUDY PROTOCOL Open Access
The Parkin’Play study: protocol of a phase II
randomized controlled trial to assess the
effects of a health game on cognition in
Parkinson’s disease
Sjors C. F. van de Weijer1, Annelien A. Duits2, Bastiaan R. Bloem3,5, Roy P. Kessels4,5, Jacobus F. A. Jansen6,7,
Sebastian Köhler7, Gerrit Tissingh8 and Mark L. Kuijf1*
Abstract
Background: In Parkinson’s disease (PD), cognitive impairment is an important non-motor symptom heralding the
development of dementia. Effective treatments to slow down the rate of cognitive decline in PD patients with mild
cognitive impairment are lacking. Here, we describe the design of the Parkin’Play study, which assesses the effects
of a cognitive health game intervention on cognition in PD.
Methods/Design: This study is a multicentre, phase-II, open-randomized clinical trial that aims to recruit 222 PD
patients with mild cognitive impairment. Eligible patients have PD, Hoehn & Yahr stages I–III, are aged between 40
and 75 years, and have cognitive impairment but no dementia. The intervention group (n = 111) will be trained
using a web-based health game targeting multiple cognitive domains. The control group (n = 111) will be placed
on a waiting list. In order to increase compliance the health game adapts to the subjects’ performance, is enjoyable,
and can be played at home. From each group, 20 patients will undergo fMRI to test for potential functional brain
changes underlying treatment. The primary outcome after 12 weeks of training is cognitive function, as assessed by
a standard neuropsychological assessment battery and an online cognitive assessment. The neuropsychological
assessment battery covers the following domains: executive function, memory, visual perception, visuoconstruction
and language. A compound score for overall cognitive function will be calculated as the mean score of all test Z-
scores based on the distribution of scores for both groups taken together. Secondary outcomes at follow-up visits
up to 24 weeks include various motor and non-motor symptoms, compliance, and biological endpoints (fMRI).
Discussion: This study aims at evaluating whether a cognitive intervention among PD patients leads to an
increased cognitive performance on targeted domains. Strengths of this study are a unique web-based health
game intervention, the large sample size, a control group without intervention and innovations designed to
increase compliance.
Trial registration: NTR5637 on 7-jan-2016
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Background
Non-motor symptoms in Parkinson’s disease (PD) are
now recognized as major contributors to a decreased
quality of life [1, 2]. Cognitive impairment is an import-
ant non-motor symptom and common in a substantial
proportion of PD patients, even in early stages of the
disease, and cognitive deficits typically worsen with dis-
ease progression [3]. Mild cognitive impairment in Par-
kinson’s disease (or PD-MCI) is an umbrella term that
refers to the heterogeneity of cognitive deficits in mul-
tiple domains. It describes the transition from healthy
aging to dementia in which cognitive dysfunction is
present, but no functional impairment [4]. PD is consid-
ered to be a fronto-striatal syndrome that gives rise to
cognitive deficits that are particularly apparent when pa-
tients need to generate behaviour on the basis of internal
rather than external cues, and when they need to flexibly
switch between well-learned tasks [5]. Salient cognitive
deficits in PD thus usually relate to deficits in attention
and executive function, yet the overall cognitive profile
is heterogeneous, with co-existing deficits in memory
and visuospatial functions also being frequent.
Current treatment strategies for the cognitive deficits
are partially effective at best. Even with optimal medical
management, cognitive impairment remains a common
and incapacitating problem for many PD patients.
Therefore, adequate strategies to improve cognitive
function and to possibly delay the onset of PD dementia
are urgently needed.
The aging brain is thought to retain some degree of
plasticity [6], which suggests that older adults may bene-
fit from cognitive training programs. Most studies on
the effect of cognitive training programs have been per-
formed in healthy older adults, or in people with cogni-
tive impairment due to vascular pathology or traumatic
brain injury. Results showed that these programs could
improve multiple domains of cognition [7–9]. So far,
only a few cognitive intervention-studies have been con-
ducted in PD patients [10–12]. Some have shown that
cognitive training programs improved memory perform-
ance [11] and overall cognitive functions [12] after only
six weeks of training. Furthermore, cognitive training
resulted in a reduced risk of developing PD-MCI at a one-
year follow up assessment [12]. Indeed, a recent system-
atic review by Leung et al. [13] demonstrated a modest
effect (g = 0.23, 95 % confidence interval 0.014–0.44, p =
0.037) of cognitive training on cognitive function in pa-
tients with mild to moderate PD. According to Leung et
al. [13], studies in larger samples are needed to examine
the abilities of a cognitive training in preventing cognitive
decline in PD.
The functional changes in the brain and mechanisms
responsible for the associated degeneration process of
MCI are unknown [14]. However, several changes in
functional connectivity between selective brain regions
also take place during this degeneration process.
Visualization of these changes helps to localize the re-
sponsible underlying mechanisms and may be used as a
tool for evaluation of future treatments. In PD-MCI,
changes in global patterns of resting-state functional
connectivity have been associated with widespread
connectivity decrements in several networks, including
the default-mode network (DMN) and occipital net-
works [3, 15, 16]. Most studies demonstrated a pro-
nounced working-memory related under-recruitment of
the striatum and dorsolateral prefrontal regions, but also
increments of the connectivity of the DMN with poster-
ior cortical regions. The under-recruitment of the stri-
atum may be associated with a reduced capacity for
working-memory updating through a decreased phasic
release of dopamine [17], but direct evidence linking
cognitive changes to underlying brain mechanisms in
PD is sparse. A longitudinal study that followed PD pa-
tients for three years mainly found functional connectiv-
ity changes in the parietal, temporal, and occipital
cortices that were associated with cognitive decline [18].
No longitudinal studies have been published on func-
tional network activity changes in PD patients during
active cognitive training.
Here, we describe the design of the Parkin’Play study,
a multi-centre randomized controlled trial (RCT) that
examines the effect of a web-based gaming service
(MyCognition AquaSnap) on cognitive function in PD
patients with cognitive impairment but no dementia.
The gaming service includes both a cognitive training
videogame (AquaSnap) and a cognitive assessment
(MyCQ™), which respectively trains and assesses the cog-
nitive functions of a player on five core cognitive do-
mains: attention, psychomotor speed, working memory,
episodic memory, and executive function. The combin-
ation of these two components ensures an intervention
adjusted to the (impaired) cognitive performance level of
the subjects. Creating a web-based and adaptive health
game that incorporates enhanced cognitive training
loops may be more engaging, which may result in an in-
creased compliance and effect in PD-MCI. The aim of
this study is to determine whether a web-based gaming
service designed for cognitive training is a feasible ap-
proach, and able to improve cognitive functioning within
a three-month time frame in a new cohort of PD-MCI
patients. We hypothesize that being able to train at
home may optimize compliance to the intervention, as it
motivates and rewards the patients.
Objectives
The primary objective of the Parkin’Play study is to
evaluate whether an individually tailored multi-domain
cognitive intervention (a health game) leads to an
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improvement in cognitive performance on various
targeted domains, such as executive function, memory,
visual perception, visuo-construction, and language. The
secondary objective is to study whether the effects per-
sists over time, after the intervention has ceased.
Additionally, given the limited number of studies
among PD-patients, it is still unclear whether cognitive
improvement due to cognitive training has a neurobio-
logical basis. To provide us with evidence for a mechan-
istic explanation for the effect of the intervention and to
locate the changes in various brain structures, we will
assess task-based and resting-state fMRI. Specifically, we
will analyse changes in connectivity patterns in the
resting-state sensorimotor network, including the sup-
plementary motor area, sensorimotor cortex, and sec-
ondary somatosensory cortex [19].
Methods/Design
Ethical approval and trial registration
The study is carried out in compliance with the Helsinki
Declaration. The local ethics committee of the Maas-
tricht University Medical Centre has approved the study
protocol, patient information letter, and the informed
consent forms. Informed consent is obtained and signed
by the patient prior to the screening session, after the
patient is fully informed about the study and the proce-
dures. The Parkin’Play study is registered in the Dutch
trial registration under registration number NTR5637.
Study design
The Parkin’Play study is a multicenter phase-II open-
randomized controlled study that aims to recruit 222 pa-
tients with Parkinson’s disease with PD-MCI. Patients are
randomly assigned to the intervention (cognitive training)
or the control group (waiting list). All participants will
undergo three assessments (t = 0, t = 1, and t = 2), which
consist of neuropsychological assessments and question-
naires. In 20 patients from each group (total n = 40) two
fMRI scans will be obtained (t = 0 and t = 1). The duration
of the main intervention will be 12 weeks. In order to in-
vestigate the compliance and attractiveness of the health
game, patients will be given the opportunity to continue
playing for an additional 12 weeks (Fig. 1). The study will
be analysed based on an intention-to-treat approach and
results will be published on behalf of the Parkin’Play
investigators.
Intervention
The total duration of the intervention will be 12 weeks
for both groups, with a voluntary extension of the cogni-
tive training for an additional 12 weeks.
Cognitive training (intervention group)
The intervention consists of a combination of two soft-
ware products. To give people insight into their cogni-
tive profile and tailor the intervention towards an
individuals’ weaknesses, the participants’ cognitive func-
tions will be assessed using an online assessment tool:
MyCognition Quotient (MyCQ™). MyCQ™ is a cognitive
assessment tool developed by the company MyCogni-
tion. Through ten individual tests, this assessment spe-
cifically evaluates the patients’ capabilities in five core
cognitive domains: attention, psychomotor speed, work-
ing memory, episodic memory, and executive function,
consistent with other standard cognitive assessment tar-
geted on Parkinson Disease [20, 21], and with the main
neuropsychological domains normally considered as be-
ing affected by PD-MCI [22]. MyCQ™ is a 30-min assess-
ment, which provides a personalized cognition score for
each individual and a profile of strengths or weaknesses
across the five core cognitive domains assessed. The
individual tests that comprise the MyCQ™ assessment
are based on validated paradigms and they are con-
sidered to be revised versions of paradigms that are
commonly employed in the assessment of human
cognition (see Table 1). The MyCQ™ was compared to
the Cambridge Neuropsychological Automated Test
Battery (CANTAB) in a population of fifty-five patients
with psychiatric disorders [23]. Results indicated that most
of the MyCQ™ subtests correlated with the CANTAB sub-
tests of the corresponding domain.
The second product is a custom-made and web-based
cognitive training AquaSnap that was built with input
from experts of both Radboud University Medical Cen-
ter and Maastricht University Medical Center. The adap-
tive cognitive training aims at exercising the cognitive
domains of attention, working memory, episodic mem-
ory, psychomotor speed and executive function. In
AquaSnap, played online on a PC/laptop or Apple iPad,
a player is required to explore the ocean in an under-
water rover and complete specific tasks by taking pic-
tures of fish. The pictures are worth currency, which can
be used to dive deeper into the sea to discover different
aquatic environments with rarer fish. The MyCQ™ as-
sessment is carried out monthly and according to an in-
dividuals’ profile, AquaSnap adapts the speed and
difficulty level of the game. The lower a player’s MyCQ™
score, the more training tasks they need to complete in
that specific domain. Each cognitive domain is mainly
trained by a particular training loop, while some do-
mains are trained across different tasks (see Table 2).
The game develops on different structural levels. At the
basic structural level there are the loops, which corre-
sponds to the five first tasks in Table 2. The loops are
organized in underwater dives, in which the player
undergoes a set of loops. At the Ocean map level, users
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Fig. 1 Design of the Parkin'Play study
Table 1 Individual MyCQ™ tests listed with test equivalents
MyCQ™ Test Cognitive domains measures Paper & pencil test equivalent Computerised test equivalent
1 Simple Reaction Time Psychomotor speed Donders Type A Detection
2 Choice Reaction Time Attention Donders Type B Identification
3 Go/No Goa Inhibition Donders Type C -
4 Verbal recognition memory Episodic memory Rey Auditory Verbal Learning Test CDR Word Recognition
5 Visual recognition memory Episodic memory Benton Visual Retention Test CDR Picture Recognition
6 1-Backa Working memory - One Back
7 2-Backa Working memory - Two Back
8 Trail Making A Praxis/psychomotor speed Trail Making Test Part A Chase Test
9 Trail Making Ba Praxis/psychomotor speed/set shifting Trail Making Test Part B Groton Maze Learning Test
10 Codinga Psychomotor speed/attention Digit Symbol Substitution Test -
aAlso indexes elements of executive function
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have to organise their dive in order to both achieve the
proposed mission and to discover new areas. The pro-
gress of the players on the map, and consequently the
growth of difficulty in the training game depend on the
coins the players are able to collect during their dives. In
this way the game adapts its difficulty to the level of pro-
gression reached by the player (Fig. 2). Additionally, as
mentioned above, the intensity of the training depends
on the individual MyCQ™ scores, as the number of loops
for each type of task depends on the score obtained on
each cognitive domain. In this way, more impaired do-
mains will receive more intensive training.
The duration of the cognitive training period is set at 12
weeks with a cumulative duration of 18 h, divided over 36
sessions. In other cognitive training studies, the mean cu-
mulative duration was 17,6 h with a range between 5 and
42 h and the mean training period was 9 weeks with a
range between 4 and 24 weeks [10, 11, 24–26].
Time spent per day on gaming will be recorded auto-
matically. There will no pre-set time limits in order to
investigate the attractiveness of the games as well as the
possibility of testing for addictive behaviour in post-hoc
analyses. To prevent attrition due to an inadequate level
of difficulty (i.e. too high or too low), coaches will con-
tact the patients every two weeks in the first month to
adjust the levels accordingly.
Waiting list (control group)
The control group is designed as a waiting list group in
order to increase compliance. The participants are re-
quired to perform the MyCQ™ assessment monthly. For
motivational purposes, the control group is offered to
take part in a deferred intervention after 12 weeks (e.g.
from week 12 until 24), with the same intensity as the
intervention group in the first 12 weeks.
Drop-outs and adverse events
Patients who drop out will be encouraged to complete
the follow-up measurements. All unwanted and harmful
outcomes spontaneously reported by the patients, that
may or not be related to the treatment (adverse events),
will be recorded according to section 10, subsection 1 of
the Dutch Research Involving Human Subjects Act
(WMO). Addiction to playing the game will be moni-
tored by recording the amount of playing time and the
BIS-11 scoring that measures changes in impulsivity. In
case of a serious adverse event, the Ethics committee
and relevant authorities (Toetsingonline and principal
investigator) will be notified immediately.
Medication adjustments
All participants are asked to keep their medication stable
during the intervention period. Nonetheless, if medica-
tion changes are presumed necessary by the treating
neurologist, they are allowed to do so. Any changes in
medication will be noted in the case report form.
Study population
In- and exclusion criteria are shown in Table 3. Patients
who are eligible for participating in the study have PD
diagnosed by an experienced neurologist, with Hoehn
and Yahr stages I–III, and are aged between 40 and 75
years. Furthermore, they have cognitive impairment but
no dementia. Neuropsychological assessment including a
global measure and a limited battery of standard tests
will be used to assess whether MCI is present in accord-
ance with the Level I criteria for the diagnosis of PD-
MCI by Litvan et al. [27]. Patients must be on relatively
Table 2 Individual tasks in AquaSnap and trained domains
AquaSnap task Description Cognitive domain
1 Memory shot Remember the position of the glowing fish in the loop Working memory
2 Quick shot Snap the fish as soon as you see it Processing speed and attention
3 Careful quick shot Snap the fish as soon as you see it, but be careful not
to snap the shocking flash
Attention and executive function (inhibition)
4 Group shot Snap the group of fish all together Attention and processing speed
5 Fish Tracker Remember which fish are glowing after they change position Working memory
6 Oceanic survey Remember which fish have you seen at the end of the dive Episodic memory
7 Missions and map exploration Achieve the goals proposed by the daily missions and try
to discover new areas on the ocean map
Executive function (planning and organizing)
Fig. 2 Feedback loops regulating the difficulty and pace of the
AquaSnap training
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stable dopaminergic medication for at least three months
prior to inclusion, or the change in medication does not
influence cognition. Patients should not receive any other
cognitive therapy during the study period. Also, gamers
who play any type of computer games more than one hour
per week in the preceding year are excluded from
participation.
Recruitment and setting
The treating neurologist will evaluate eligibility of pa-
tients using a checklist. After eligible patients have been
informed about the study and have agreed to participate,
they will be invited for a screening assessment. Informed
consent is signed prior to the screening assessment. The
inclusion period for the Parkin’Play study will last 18
months. In order to reach target sample size, neurolo-
gists from Maastricht University Medical Center, Rad-
boud University Medical Center Nijmegen, and
Zuyderland Medical Center Heerlen will be involved in
recruitment. Participants are currently being recruited
and enrolled. For practical reasons, only patients from
Maastricht University Medical Center will be asked to
join the fMRI sub-study, prior to the screening assess-
ment. We stop including fMRI participants when the
goal of 20 patients per arm is reached.
Randomization and blinding
After the baseline measurements are performed, partici-
pants will be randomly assigned to one of two groups:
the Intervention group (IG), or the Control group placed
on a waiting list (CG), in a 1:1 ratio. Randomisation
(minimisation) will be performed by the Clinical Trial
Centre Maastricht (not formally involved in the study or
assessments) using the software package ALEA
(Formsvision BV). Stratification factors include site loca-
tion (Maastricht, Nijmegen, or Heerlen) and age group
(<60 and > =60 years old). The study is an open-
randomised controlled trial, so there will be no blinding
for treatment allocation. Nonetheless, all follow-up mea-
surements will be assessed by blinded outcome assessors.
Patients will be enrolled by a coordinating investigator,
who assigns patients to the intervention groups.
Outcome measures
The primary outcome is global cognitive function, as
assessed by both a standard neuropsychological assess-
ment and the MyCQ™, at baseline and 12 weeks after
baseline assessment. The standard neuropsychological
assessment consists of various tests covering the follow-
ing domains: executive function (Stroop Colour Word
Test [28], category fluency and letter fluency in parallel
versions [29]), memory (Rey Auditory Verbal Learning
Test in parallel versions [30], Location Learning Test
[31]), visual perception (Judgement of Line Orientation
in parallel versions [32]), visuoconstruction (Rey-Oster-
rieth Complex Figure [33, 34]), and language (Boston
Naming Test – Short Form). A compound score for
overall (global) cognitive function will be calculated as
the mean score of all test Z-scores based on the distribu-
tion of scores for both groups taken together. Z-scores
of tests with higher scores representing worse perform-
ance will be inverted before computing the compound
scores. By comparing Z-scores across different neuro-
psychological tests, the neuropsychological profiles of
participants can be directly compared to identify the do-
mains that benefitted most from the intervention.
The participants will also perform a monthly web-
based online neuropsychological assessment (MyCQ™),
which is part of the intervention program. Since the
MyCQ™ is integrated in the AquaSnap health game (i.e.,
the difficulty level of the game automatically adapts ac-
cording to MyCQ™ performance), it is not an independ-
ent measure of treatment effects, and hence the
standard neuropsychological test battery is the primary
outcome measure.
Table 3 In- and exclusion criteria
Inclusion criteria Exclusion criteria
Idiopathic Parkinson’s disease diagnosed by a neurologist Medication affecting cognition (such as anticholinergic drugs,
benzodiazepine and methylfenidate)
Hoehn & Yahr stage ≤3 Other medical conditions:
o Advanced problems in cognitive functioning (MoCA <19/30)
o Dementia
o Active depression or psychosis and/or treatment with anti-
depressant or anti-psychotic drugs
o History of active thyroid disease, stroke with residual deficits, severe
hypertension or diabetes or head trauma interfering in cognition
Age 40-75 years Severe auditory of visual deficits
Mild cognitive impairment according to MDS (MCI Level 1 criteria) No internet at home
Relatively stable dopaminergic medication dose for at least three months
prior to the study, or change in medication does not influence cognition.
Deemed unlikely to start or stop treatment within the next three months.
fMRI sub-study:
o Metal in the body
o Claustrophobia
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Additional study parameters
Non-motor symptoms
Several assessments will be performed at baseline. The
Montreal Cognitive Assessment (MoCA) is used to as-
sess global cognition and it is suggested to be more sen-
sitive to cognitive impairment in PD populations in
comparison with the Mini Mental State Exam (MMSE)
[35]. MoCA includes several neuropsychological items
focussing on memory, language, executive function, and
visuospatial processing [36]. The Dutch National Adult
Reading Task (NART) estimates premorbid intelligence
levels. The test is untimed and consists of 50 words with
atypical phonemic pronunciation. Each word is pre-
sented individually and subjects are asked to read them
out loud [37].
Depression will be assessed with the Hamilton Anxiety
and Depression Scale (HADS) [38], which has been vali-
dated in PD [39]. The Epworth Sleepiness Scale is used
to provide a measurement of the subject’s general level
of daytime sleepiness [40]. The Cognitive Failure Ques-
tionnaire (CFQ) contains 25 questions and provides a
self-report evaluation of perception, memory and motor-
function in daily life [41]. The Parkinson’s Disease Cog-
nitive Functional Rating Scale (PD-CFR) is a 12-item
questionnaire for rating functional abnormalities associ-
ated to cognitive impairment in non-demented PD pa-
tients [42]. The pre-Rasch-built Overall Disability Scale
(pre-R-ODS) can be used to capture functional disability
of the patients in a descriptive way [43]. Quality of life
will be assessed with the Parkinson Disease Question-
naire (PDQ-39) [44]. The Barratt Impulsiveness Scale 11
(BIS-11) is a 30-item self-report questionnaire that mea-
sures impulsive behaviour [45].
Motor functioning
The unified Parkinson’s disease rating scale (MDS-
UPDRS) part III is used to assess and monitor disability
and impairment in PD patients.
Compliance
Compliance and attractiveness of the health game will
be determined based on the number of dropouts and the
cognitive training duration in both groups. Additionally,
extended compliance in the intervention group, who
continue to play the health game between 12 and 24
weeks from baseline, will be tracked. Comparable studies
among both healthy subjects as well as PD patients have
found increased cognitive abilities after 6 months follow-
up [46, 47] and 1 year follow-up [12]. Based on these
studies, we expect to find long term benefits of Aqua-
Snap. Moreover, with a 24 week follow-up measurement,
we’re able to test the feasibility of the intervention based
on the motivation of the subjects to continue playing
AquaSnap.
fMRI
MRI imaging will be performed on a 3.0-Tesla unit and in
the ON-medication state. Imaging will consist of a neurora-
diological protocol (T1-weighted sequences), supplemented
with full brain functional imaging (N-back fMRI and
resting-state fMRI for functional connectivity imaging). T1
scans will be used to assess macro-structural findings.
Volumetric assessment of T1-weighted images will be per-
formed using FreeSurfer software. Task based fMRI will be
assessed using SPM and resting state fMRI will be assessed
using Melodic. In addition, changes in the resting-state sen-
sorimotor network, including the supplementary motor
area, sensorimotor cortex, and secondary somatosensory
cortex [19], will be analysed using a robust data-driven ap-
proach: independent component analysis (ICA) [48, 49].
Imaging will be performed at the Department of Radiology
of the Maastricht University Medical Center. The assessors
performing the fMRI baseline and follow-up assessments
are blinded for treatment allocation.
Study activities
Enrolment will take place in the weeks prior to baseline
assessment, except for the additional inclusion assess-
ments (see Table 4). The following demographics and
general variables are collected at baseline: date of birth,
sex, educational level, age at onset, disease duration, and
details on Parkinson medication (i.e., drug name, dose,
frequency, levodopa equivalence). Details on Parkinson
medication will also be collected at both follow-up mea-
surements. Randomization will be performed after the
baseline assessment. Primary and additional outcome as-
sessments will be performed at baseline, after 12 and
after 24 weeks follow up. The additional fMRI scans will
be performed at baseline and after 12 weeks, matching
the primary outcome assessments. The intervention
group will be required to play the health game from start
of the intervention until week 12 for at least 36 sessions
of 30 min (three times a week). After week 12, both the
intervention as well as the control group will be allowed
to continue playing the health game free of choice. All
patients will be examined in their on-state.
Data collection and management
All personnel involved in data collection will review the
standard operating procedures (SOP) and manuals. As-
sessors will be certified in Good Clinical Practice (GCP),
certified in performing the MDS-UPDRS-III, and trained
in assessing the neuropsychological test battery and
other assessments by experienced raters. Data will be
collected on paper forms and entered into a web-based
data entry portal. Questionnaires are completed digitally
and are imported automatically in the electronic data-
base, of which a backup will be made daily. A member
of the research team will monitor inclusion progress and
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data collection progress. After completion of the Parkin’-
Play study, the database will be approved and locked be-
fore data-analysis is set in motion.
Statistical analysis procedure
Differences between the intervention and control group
in global cognitive function (compound score of the
neuropsychological test battery) at 12 weeks (primary
endpoint) will be compared using independent sample t-
tests. In addition, differences between groups in the
individual cognitive domains will be tested using multi-
variate analysis of variance (MANOVA). Change in cog-
nition over time (baseline, 12 weeks, 24 weeks) will be
tested using repeated-measures ANOVA. All tests will
be two-tailed with alpha set at 0.05. The assumptions of
normality and homogeneity of variance will be assessed
by inspection of normal probability plots and residual
plots. In case assumptions are not met, appropriate data
transformations will be used. Secondary outcomes will
be presented as means, standard deviations, minimum,
maximum, median, lower and upper quartiles. The num-
ber of observations and changes from baseline will be
presented. Categorical data will be presented in contin-
gency tables as frequencies and percentages. The ana-
lyses will be performed on an intention-to-treat basis. A
secondary “Per-Protocol” analysis will also be included
for the patients who have fully completed the study
protocol for the primary endpoint. In order to investi-
gate the effect of ‘missingness’, sensitivity analyses will
be performed, including missing data augmentation
using multiple imputation by chained equations [45] and
maximum likelihood estimation with random effects.
For the main study, interim analysis will be conducted
after 40 patients have completed the 12-week cognitive
training period, including the corresponding assess-
ments, to find out if the training is particularly beneficial
or not. If, after interim analysis, it can be concluded that
the training is particularly harmful, we may end the
study and analyze the study data. This will only be de-
cided in consultation with the local ethics committee.
Table 4 Study schedule and assessments
Timepoint→ -t1 t0 t1 t2
Visit # → 0 1 2 3
Week # → -1 to -3 0 4 8 12 24
ENROLMENT:
Screening & inclusion assessments
Regular clinical intake X
Demographics X
Inclusion/exclusion X
National Adult Reading Task X
Montreal Cognitive Assessment X
Epworth Sleepiness X
Levodopa equivalent dose (LED) X X X
ASSESSMENTS:
Primary outcomes
Standard neuropsychological battery X X X
MyCQ™ assessment X X X X X
Additional outcomes
Motor function (UPDRS part III) X X X
Self-report questionnaires X X X
Parkinson Disease Questionnaire-39 X X X
Pre-Rasch-built Overall Disability Scale X X X
fMRI exclusion criteria X
fMRI scan X X
INTERVENTIONS
Randomization X
Game playing (36 sessions of 30 min) X X X X X
Only for subset of patients (n = 40)
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Power and sample size estimate
The Parkin’Play study is powered to show a moderate effect
of the AquaSnap cognitive training on the standard neuro-
psychological assessment. A study in healthy older partici-
pants compared a brain training program (Brain Age) to a
control condition (Tetris gaming) and found an ANCOVA-
based effect size of Cohen’s f = 0.39 (eta2 = 0.13) on the
Trail Making Test, which assesses cognitive flexibility, often
reduced in PD [9]. This reflects a moderate-to-large effect
size (equivalent of Cohen’s d of 0.78). The present popula-
tion includes participants aged between 40 and 75 years
old, but with PD. Still, we expect a moderate effect size
(0.4–0.5). Therefore, the estimated sample size for detecting
a difference between the means of the treatment groups on
the compound score of standard neuropsychological tests,
with a power of 0.8 and a Cohen’s d = 0.4, at an alpha-level
of 0.05, for a two-sided test, and an allocation ratio of 1:1 is
200 patients.
Based on previous cognition training and video game
clinical trials the attrition rate is estimated at 10 %,
which yields an additional 22 patients that should be re-
cruited for participation [9, 11, 50]. This leaves a total of
222 patients that should be recruited.
Discussion
The overall aim of this phase-2 multi-center open-
randomized controlled clinical trial among PD patients
is to evaluate whether a web-based health game designed
to train cognition leads to an improvement in cognitive
performance on targeted cognitive domains, relative to a
control group on a waiting list. The strengths of the Par-
kin’Play study are the large sample size (n = 222), the
gamified and home-based training approach, the indi-
vidually tailored and adaptive training, and the applica-
tion of fMRI assessments in order to explore underlying
brain mechanisms. The addition of the 24-week follow
up assessment provides valuable information about
maintenance of benefit and about the feasibility of
implementing health games in a PD population.
Now that the new MDS-criteria for PD-MCI have
been introduced, this study will for the first time study a
large sample of patients fulfilling the proposed criteria in
a clinical trial [13]. Previous cognitive clinical trials for
PD have incorporated a range of cognitive and func-
tional outcome measures, partly based on scales derived
from Alzheimer’s disease [51, 52]. This illustrates the
lack of consensus on cognitive outcome measures. Fur-
thermore, regulatory agencies may require measures that
take into account a functional benefit for the patient. In
this study, a compound score from a neuropsychological
test battery will be used and complemented with the
MyCQ™. The recently validated PD-CFRS scale was
chosen to study functional benefit with demonstrated re-
sponsiveness over time [53].
The Parkin’Play intervention consists of various inno-
vations. Firstly, performing cognitive training at home is
likely to optimize compliance, since PD patients’ re-
duced mobility might prevent them from attending out-
door activities [12, 47]. Secondly, a task that is too hard
may result in anxiety and therefore lead to resistance of
collaboration to the treatment (e.g. stop playing the
health game). The health game and MyCQ™ assessment
combination adapts to the subject’s capabilities and
thereby results in a challenging game specifically tailored
to the individual. Thirdly, the health game aims at being
fun to play, introducing a multi-layer game story op-
posed to abstract repetitive cognitive brain trainings.
These innovations are aimed at increasing the compli-
ance of the intervention and prevent substantial attrition
rates associated with study failures.
Cognitive training is thought to have beneficial effects
on cognitionthrough activating mechanisms of the brain
plasticity. Brain plasticity refers to the capacity of the cen-
tral nervous system to change or to adapt its structure
and function over a lifetime [54, 55]. There is evidence
that training on demanding tasks (adaptive training) de-
creases activation in frontal, parietal, and occipital regions
of older adults, which may reflect improved neural effi-
ciency and reduced use of resources [56]. Cognitive train-
ing has proved to be able to produce improvement in the
main neuropsychological domains involved in PD as
memory, attention, processing speed and executive func-
tion. Specific studies on the effects of cognitive training
on PD have recently been conducted [26]. The results of
randomized control trials show that cognitive and affective
functions can be improved by cognitive trainings in PD
patients. To our knowledge, no cognitive videogame train-
ing interventions have been conducted in PD-MDI.
Mild cognitive impairment in PD is generally viewed as a
pre-dementia stage in PD, but the functional changes in the
brain and mechanisms responsible for the associated de-
generation process are unknown. Since the aged brain still
retains neuroplasticity [6], it may restore or prevent func-
tional changes of brain network activity. Indeed, in a non-
imaging study, Petrelli et al. [12] have found that patients in
the cognitive training intervention group had a reduced risk
of developing MCI after 1 year follow up. Nonetheless, no
longitudinal studies have been published on functional
changes in PD patients during cognitive training. With the
use of fMRI-imaging, we hope to have a better understand-
ing on functional network activity changes in PD patients
as a result of active cognitive training. Visualization of these
changes helps to localize the responsible underlying mecha-
nisms and may be used as a tool for evaluation of future
treatments.
The Parkin’Play study contributes to a better understand-
ing of cognitive impairment in PD and evaluates a new pos-
sible non-pharmacological intervention for PD-MCI.
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